Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Merck & Co., Inc. — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $29.06, while Merck & Co., Inc. trades at $126.98 (market cap $305.29B). The key difference: Merck & Co., Inc. pays a 2.75% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and Merck & Co., Inc. is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| FNGU | MRK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $129.52 |
52-Week Low | $13.73 | $77.60 |
Market Cap | — | $305.29B |
Enterprise Value | — | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $28.77, down 0.45% on the day. The technical picture is mixed, with moving averages signaling bullish momentum but oscillators and a high RSI indicating overbought conditions. Recent news highlights the extreme volatility and decay inherent to its leveraged structure, with one report noting a $10,000 position losing 16% in a single session in June 2026.
The outlook is dominated by the product's high-risk, tactical nature. The opportunity lies in capturing amplified gains during strong bullish trends in mega-cap tech. The primary risk is significant capital erosion during volatile or sideways markets due to daily resetting leverage and compounding costs, making it unsuitable for long-term holding.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
